Literature DB >> 11514733

In situ hybridization and immunolabelling study of the early replication of simian immunodeficiency virus (SIVmacJ5) in vivo.

Carmen Cantó-Nogués1, Sue Jones1, Rebecca Sangster1, Peter Silvera1, Robin Hull1, Roger Cook2, Graham Hall2, Barry Walker1, E Jim Stott1, David Hockley1, Neil Almond1.   

Abstract

The distribution of virus-infected cells in cynomolgus macaques was determined at 4, 7, 14 and 28 days following intravenous challenge with 1000 TCID(50) of the wild-type simian immunodeficiency virus SIVmacJ5 (stock J5C). At each time-point, pairs of macaques were killed humanely and the presence of SIV was determined and quantified in blood, spleen, peripheral and mesenteric lymph nodes, thymus, lung and ileum by virus co-cultivation with C8166 cells, by quantitative DNA PCR or by in situ hybridization (ISH). At day 4 post-infection (p.i.), detection of the virus was sporadic. By day 7 p.i., however, significant SIV loads were detected in the blood and lymphoid tissues by DNA PCR and virus co-cultivation. Large numbers of cells expressing SIV RNA were detected in mesenteric lymph nodes by ISH and significantly fewer (P<0.05) in the spleen. Significant numbers of ISH-positive cells were also observed in sections of ileum. By day 14 p.i., the distribution of SIV was more even in all lymphoid tissues analysed. By day 28, most of the tissues were negative by ISH, but all remained positive by virus isolation and DNA PCR. Immunolabelling of sections of mesenteric lymph node with monoclonal antibodies specific for SIV envelope and Nef largely confirmed the observations from ISH. These results indicate that, even following intravenous challenge, a major site of the initial replication of SIV is gut-associated lymphoid tissue. Vaccines that induce protection at this site may therefore be superior, even against parenteral challenge.

Entities:  

Mesh:

Year:  2001        PMID: 11514733     DOI: 10.1099/0022-1317-82-9-2225

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Enhanced replication of simian immunodeficiency virus adjacent to catecholaminergic varicosities in primate lymph nodes.

Authors:  Erica K Sloan; Ross P Tarara; John P Capitanio; Steve W Cole
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

2.  HIV-1 infection of neurons might account for progressive HIV-1-associated encephalopathy in children.

Authors:  Carmen Cantó-Nogués; Silvia Sánchez-Ramón; Susana Alvarez; César Lacruz; Ma Angeles Muñóz-Fernández
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

3.  Antigenic stimulation specifically reactivates the replication of archived simian immunodeficiency virus genomes in chronically infected macaques.

Authors:  Céline Renoux; Simon Wain-Hobson; Bruno Hurtrel; Rémi Cheynier
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  SIV infection decreases sympathetic innervation of primate lymph nodes: the role of neurotrophins.

Authors:  Erica K Sloan; Christina T Nguyen; Benjamin F Cox; Ross P Tarara; John P Capitanio; Steve W Cole
Journal:  Brain Behav Immun       Date:  2007-09-17       Impact factor: 7.217

5.  Neuropathology of wild-type and nef-attenuated T cell tropic simian immunodeficiency virus (SIVmac32H) and macrophage tropic neurovirulent SIVmac17E-Fr in cynomolgus macaques.

Authors:  Sean Clarke; Neil Berry; Claire Ham; Jack Alden; Neil Almond; Debbie Ferguson
Journal:  J Neurovirol       Date:  2012-03-09       Impact factor: 2.643

6.  Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques.

Authors:  Neil Berry; Claire Ham; Edward T Mee; Nicola J Rose; Giada Mattiuzzo; Adrian Jenkins; Mark Page; William Elsley; Mark Robinson; Deborah Smith; Deborah Ferguson; Greg Towers; Neil Almond; Richard Stebbings
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

7.  Live attenuated simian immunodeficiency virus vaccination confers superinfection resistance against macrophage-tropic and neurovirulent wild-type SIV challenge.

Authors:  Neil Berry; Claire Ham; Jack Alden; Sean Clarke; Richard Stebbings; Jim Stott; Deborah Ferguson; Neil Almond
Journal:  J Gen Virol       Date:  2015-04-01       Impact factor: 3.891

8.  Conditionally-live attenuated SIV upregulates global T effector memory cell frequency under replication permissive conditions.

Authors:  Maria S Manoussaka; Neil Berry; Deborah Ferguson; Richard Stebbings; Mark Robinson; Claire Ham; Mark Page; Bo Li; Atze T Das; Ben Berkhout; Neil Almond; Martin P Cranage
Journal:  Retrovirology       Date:  2013-06-05       Impact factor: 4.602

9.  Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissues.

Authors:  Deborah Ferguson; Giada Mattiuzzo; Claire Ham; Richard Stebbings; Bo Li; Nicola J Rose; Edward T Mee; Deborah Smith; Mark Page; Martin P Cranage; Neil Almond; Greg J Towers; Neil J Berry
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

10.  Attenuated SIV causes persisting neuroinflammation in the absence of a chronic viral load and neurotoxic antiretroviral therapy.

Authors:  Deborah Ferguson; Sean Clarke; Neil Berry; Neil Almond
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.